Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10239911B2 · kind B2 · utility
12Cited by
173References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 6, 2018 |
| Grant date | Mar 26, 2019 |
| Priority date | — |
| Expiry date | Jun 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.